Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

239 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-03-27

Study Completion Date

2020-09-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The overall objective of the study is to determine the therapeutic effect and tolerance of Sarilumab in patients with moderate, severe pneumonia or critical pneumonia associated with Coronavirus disease 2019 (COVID-19). Sarilumab is a human IgG1 monoclonal antibody that binds specifically to both soluble and membrane-bound IL-6Rs (sIL-6Rα and mIL-6Rα) and has been shown to inhibit IL-6-mediated signaling through these receptors. The study has a cohort multiple Randomized Controlled Trials (cmRCT) design. Randomization will occur prior to offering Sarilumab administration to patients enrolled in the CORIMUNO-19 cohort. Sarilumab will be administered to consenting adult patients hospitalized with COVID-19 either diagnosed with moderate or severe pneumonia requiring no mechanical ventilation or critical pneumonia requiring mechanical ventilation. Patients who will chose not to receive Sarilumab will receive standard of care. Outcomes of Sarilumab-treated patients will be compared with outcomes of standard of care-treated patients as well as with outcomes of patients treated with other immune modulators.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Sarilumab for Patients With Moderate COVID-19 Disease

NCT04359901

COVID

COMPLETED PHASE2

Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients

NCT04464395

COVID-19

COMPLETED PHASE1

Safety and Tolerability of Regeneron Anti-SARS-CoV-2 Monoclonal Antibody/Ies in Adult Healthy Volunteers as Related to COVID-19

NCT05293678

Healthy

COMPLETED PHASE1

Randomized, Single-blinded, Multicenter Trial Comparing the Immune Response to a 2nd Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNTech) or Sanofi /GSK B.1.351 Adjuvanted Vaccine in Adults

NCT05405283

COVID-19 Vaccines

UNKNOWN PHASE3

SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine

NCT04952402

Covid19 SARS-CoV2 Infection

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Corona Virus Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Bayesian open labelled randomized clinical trial

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SARILUMAB -- Severe COVID population (WHO Clinical Progression Scale =5 at baseline)

Sarilumab (an IV dose of 400 mg of sarilumab in a 1 hour-infusion at Day 1). Administration of Sarilumab fixed dose on day 3 was recommended and left to the treating physician

Group Type EXPERIMENTAL

Sarilumab

Intervention Type DRUG

(an IV dose of 400 mg of sarilumab in a 1 hour-infusion at D1

Standard of care -- Severe COVID population (WHO Clinical Progression Scale =5 at baseline)

Usual care was provided at the discretion of the clinicians

Group Type NO_INTERVENTION

No interventions assigned to this group

SARILUMAB -- Critical COVID population (WHO Clinical Progression Scale >5 at baseline)

Sarilumab (an IV dose of 400 mg of sarilumab in a 1 hour-infusion at Day 1). Administration of Sarilumab fixed dose on day 3 was recommended and left to the treating physician

Group Type EXPERIMENTAL

Sarilumab

Intervention Type DRUG

(an IV dose of 400 mg of sarilumab in a 1 hour-infusion at D1

Standard of care -- Critical COVID population (WHO Clinical Progression Scale >5)

Usual care was provided at the discretion of the clinicians

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sarilumab

(an IV dose of 400 mg of sarilumab in a 1 hour-infusion at D1

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients included in the CORIMUNO-19 cohort
2. Patients belonging to one of the 2 following groups:

* Group 1: patients not requiring Intensive Care Unit at admission with moderate and severe pneumopathy according to the OMS Criteria of severity of COVID pneumopathy.

Moderate cases :

Cases meeting all of the following criteria:

* Showing fever and respiratory symptoms with radiological findings of pneumonia.
* Requiring between 3L/min and 5L/min of oxygen to maintain SpO2 \>97% Severe cases

Cases meeting any of the following criteria:

* Respiratory distress (≧30 breaths/ min);
* Oxygen saturation≤93% at rest in ambient air; or Oxygen saturation ≤97 % with O2 \> 5L/min.
* PaO2/FiO2≦300mmHg
* Group 2: patients requiring Intensive Care Unit based on Criteria of severity of COVID pneumopathy.
* Respiratory failure and requiring mechanical ventilation
* No do-not-resuscitate order (DNR order)

Exclusion Criteria

* Known hypersensitivity to Sarilumab or to any of their excipients.
* Pregnancy
* Current documented bacterial infection
* Patient with any of following laboratory results out of the ranges detailed below at screening should be discussed depending of the medication:
* Absolute neutrophil count (ANC) ≤ 1.0 x 109/L
* Haemoglobin level: no limitation
* Platelets (PLT) \< 50 G /L
* SGOT or SGPT \> 5N

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No